CAS:1460272-53-0|4-((3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorophenyl)(hydroxy)methyl)phthalazin-1(2H)-one

CAS:1460272-53-0|4-((3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorophenyl)(hydroxy)methyl)phthalazin-1(2H)-one

Catalogue Number:C992278
Chemical Name:4-((3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorophenyl)(hydroxy)methyl)phthalazin-1(2H)-one
Synonyms:Olaparib Metabolite M15
CAS Number:1460272-53-0
Molecular Formula:C₂₄H₂₃FN₄O₄
Appearance:White to Off-White Solid
Melting Point:234 – 238°C
Molecular Weight:450.46
Storage:-20°C, Inert atmosphere
Solubility:DMSO (Slightly), Methanol (Slightly, Sonicated)
Category:Research Tools; Molecular Biology; Enzyme Activators and Inhibitors;
Applications:4-((3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorophenyl)(hydroxy)methyl)phthalazin-1(2H)-one is an impurity of Olaparib (O514500), a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy. Potent PARP inhibitor.
References:Weston, V.J. et al.: Blood, 116, 4578 (2010); Senra, J.M. et al.: Mol. Cancer Therap., 10, 1949 (2011); Schaefer, N.G. et al.: Nuc. Med. Comm., 32, 1046 (2011);
To ensure the stability of our products, the efficient express delivery service will be used. We also guarantee that the products will be shipped in the box with layers of tapes to protect them against damage. The extremely low temperature products will be wrapped with dried ice, and the low temperature products will be delivered with ice bags. As for the products stored at room temperature, they will not be packed with ice bags or dried ice. Taskcm is committed to providing cost-effective products that facilitate drug delivery with our customers.
Email:sales@ebclink.com

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *